CLINICAL_TRIALS
trial_result
· 2025-03-12
Clinical Trial Update: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study [Phase 3]
Summary
Phase 3 long-term safety and efficacy surveillance trial of Coversin (rVA576) in paroxysmal nocturnal hemoglobinuria was terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AKARI Therapeutics | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: TERMINATED | Results posted: 2025-03-12